Skip to main content
. 2022 Oct 31;10(11):2758. doi: 10.3390/biomedicines10112758

Figure 1.

Figure 1

Kaplan–Meier estimates according to bone metastases for patients treated with ipilimumab plus nivolumab for (A) overall survival and (B) progression-free survival in the global cohort. Kaplan–Meier estimates according to bone metastases for patients treated with ipilimumab plus nivolumab for (C) overall survival and (D) progression-free survival in renal cell carcinoma.